infoTECH News

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, will make a
presentation regarding the company on January 14, 2014, at 11:00 A.M. PT
during the 32nd Annual J.P. Morgan Healthcare Conference in
San Francisco. A question and answer session with investors will follow
the presentation.

The presentation and the question and answer session will be webcast
live and can be accessed by visiting the Investor homepage section of
Enanta's website at www.enanta.com.
A replay of the presentation and question and answer session will be
available following the sessions and will be archived for approximately
60 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes - protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase - as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.